Sedana Medical AB (publ) updates the schedule for the IsoConDa study.
Sedana Medical AB ("Sedana Medical or the Company") announces that the schedule for patient recruitment in the ongoing Phase 3 IsoConDa study is likely to be extended.Performing clinical studies in the intensive care unit is challenging as most patients are in a critical condition and are often unconscious when included in the study. The guidelines for how to recruit these patients are strictly followed but leave some room for interpretation. In connection with an inspection of the study, a local authority has criticized certain aspects of the approach for the inclusion of some unconscious